$6.94
4.28% day before yesterday
NYSE, May 30, 10:00 pm CET
ISIN
US37611X1000
Symbol
DNA

Ginkgo Bioworks Stock price

$6.95
-0.42 5.70% 1M
-2.66 27.68% 6M
-2.87 29.23% YTD
-15.42 68.93% 1Y
-121.45 94.59% 3Y
-397.85 98.28% 5Y
-397.85 98.28% 10Y
NYSE, Closing price Fri, May 30 2025
-0.30 4.14%
ISIN
US37611X1000
Symbol
DNA
Sector

Key metrics

Market capitalization $406.80m
Enterprise Value $-110.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.32
EV/Sales (TTM) EV/Sales -0.46
P/S ratio (TTM) P/S ratio 1.71
P/B ratio (TTM) P/B ratio 0.59
Revenue growth (TTM) Revenue growth 13.76%
Revenue (TTM) Revenue $237.42m
EBIT (operating result TTM) EBIT $-392.32m
Free Cash Flow (TTM) Free Cash Flow $-345.30m
Cash position $516.92m
EPS (TTM) EPS $-8.70
P/E forward negative
P/S forward 2.30
EV/Sales forward negative
Short interest 25.47%
Show more

Is Ginkgo Bioworks a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Ginkgo Bioworks Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ginkgo Bioworks forecast:

1x Buy
17%
1x Hold
17%
4x Sell
67%

Analyst Opinions

6 Analysts have issued a Ginkgo Bioworks forecast:

Buy
17%
Hold
17%
Sell
67%

Financial data from Ginkgo Bioworks

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
237 237
14% 14%
100%
- Direct Costs 47 47
16% 16%
20%
190 190
13% 13%
80%
- Selling and Administrative Expenses 224 224
48% 48%
94%
- Research and Development Expense 359 359
35% 35%
151%
-327 -327
31% 31%
-138%
- Depreciation and Amortization 66 66
2% 2%
28%
EBIT (Operating Income) EBIT -392 -392
27% 27%
-165%
Net Profit -472 -472
45% 45%
-199%

In millions USD.

Don't miss a Thing! We will send you all news about Ginkgo Bioworks directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ginkgo Bioworks Stock News

Neutral
PRNewsWire
11 days ago
BOSTON , May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Ac...
Neutral
Business Wire
24 days ago
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renego...
Neutral
Seeking Alpha
26 days ago
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Mark Massaro - BTIG Tejas Savant - Morgan Stanley Evie Koslosky ...
More Ginkgo Bioworks News

Company Profile

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jason Kelly
Employees 1,218
Founded 2008
Website investors.ginkgobioworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today